Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relative Potency of Maralixibat and Volixibat in Overweight and Obese Adults
NCT02475317Phase 1Completed
- Sponsor
- Mirum Pharmaceuticals, Inc.
- Start
- Jun 2015
- Primary completion
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of maralixibat and volixibat in obesity and Overweight (8 arms), sponsored by Mirum Pharmaceuticals, Inc. Primary endpoint: Change From Baseline of Fecal Bile Acid Excretion After Dosing at Day 7. Started Jun 2015; status: completed.
02
Drugs
maralixibatvolixibat
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT02475317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02475317.